Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial
接受伊马替尼辅助治疗5年以治疗已切除的中高危原发性胃肠道间质瘤患者的疗效和耐受性：PERSIST-5临床试验
期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2018.4060
Raut, Chandrajit P; Espat, N Joseph; Maki, Robert G; Araujo, Dejka M; Trent, Jonathan; Williams, Toni Faith; Purkayastha, D Das; DeMatteo, Ronald P
